Treatment of Recurrent Bladder Cancer With Dendritic Cells

• Status: Recruiting
• Trial end date: 2020-12-31
• Target enrollment: 25
• Participant gender: Male

Summary

Treatment of recurrent bladder cancer with dendritic cells

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
• Collaborator: Belarusian State Medical University

Criteria

Inclusion Criteria:

• Histologically confirmed diagnosis of pTa bladder cancer;

• Patient who require repetitive transurethral resection;

• Expression of muc-1/wt-1 by the tumor;

• EGOC 0-3;

Exclusion Criteria:

• any medical condition which can be associated with the high risk for the patient;

• pregnancy/lactation;

• chronic infections, including hepatitis B/C, tuberculosis, HIV